Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-293-0 | CAS number: 137-42-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- secondary literature
- Justification for type of information:
- Data is from secondary source
Data source
Referenceopen allclose all
- Reference Type:
- review article or handbook
- Title:
- Developmental study of Metam-sodium in Rats
- Author:
- Linda L. Carlock
- Year:
- 2 001
- Bibliographic source:
- Handbook of Pesticide Toxicology, Chapter 87, Volume 2.2001
- Reference Type:
- secondary source
- Title:
- Metam-sodium: developmental toxicity study in rats
- Author:
- US EPA
- Year:
- 1 994
- Bibliographic source:
- United states environment protaction agecny, 1994
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: as below
- Principles of method if other than guideline:
- Teratology study of Metam-sodium in Rats
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Metam-sodium
- EC Number:
- 205-293-0
- EC Name:
- Metam-sodium
- Cas Number:
- 137-42-8
- Molecular formula:
- C2H5NS2.Na
- IUPAC Name:
- sodium (methylcarbamothioyl)sulfanide
- Details on test material:
- SMILES:CNC(=S)S{-}.[Na]{+}
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Metam-sodium
- Molecular formula (if other than submission substance): C2H4NNaS2
- Molecular weight (if other than submission substance): 129.1826 g/mole
- Substance type: Organic
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- - Source: Barriered animal breeding unit at Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, UK
Administration / exposure
- Route of administration:
- oral: gavage
- Type of inhalation exposure (if applicable):
- not specified
- Vehicle:
- not specified
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: An aqueous solution of metam sodium (42.2%) was administered at 0, 5, 20 and 60 mg/kg by gavage to pregnant Wistar rats
- Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- not specified
- Duration of treatment / exposure:
- 11 days
- Frequency of treatment:
- Daily
- Duration of test:
- Days 6-12 of gestation
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day
- Dose / conc.:
- 5 mg/kg bw/day
- Dose / conc.:
- 20 mg/kg bw/day
- Dose / conc.:
- 60 mg/kg bw/day
- No. of animals per sex per dose:
- not specified
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- not specified
Examinations
- Maternal examinations:
- Clinical signs, body weight gain, food consumption and food efficiency were examined.
- Ovaries and uterine content:
- Not specified
- Fetal examinations:
- Fetal weights, Gross pathology and histopathology was examined.
- Statistics:
- Not specified
- Indices:
- Not specified
- Historical control data:
- Not specified
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- When treated wtih 20 and 60 mg/kg/day, Piloerection, salivation, and urinary incontinence were observed in treated rats.
When treated wtih 5 mg/kg/day, No clinical signs were observed in treated rats. - Dermal irritation (if dermal study):
- not specified
- Mortality:
- not specified
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- When treated wtih 20 and 60 mg/kg/day, decreased in body weight gain was observed in treated female rats as compared to control.
When treated wtih 5 mg/kg/day, marginal decreased in body weight gain was observed in treated female rats as compared to control. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- When treated wtih 20 and 60 mg/kg/day, decreased in food consumption was observed in treated female rats as compared to control.
When treated wtih 5 mg/kg/day, marginal decreased in food consumption was observed in treated female rats as compared to control. - Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
Maternal developmental toxicity
- Number of abortions:
- not specified
- Pre- and post-implantation loss:
- not specified
- Total litter losses by resorption:
- not specified
- Early or late resorptions:
- not specified
- Dead fetuses:
- not specified
- Changes in pregnancy duration:
- not specified
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not specified - Changes in number of pregnant:
- not specified
- Other effects:
- not specified
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- 5 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- clinical signs
- Remarks on result:
- other: No effect observed
Maternal abnormalities
- Abnormalities:
- not specified
- Localisation:
- not specified
- Description (incidence and severity):
- not specified
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- When treated wtih 20 and 60 mg/kg/day, decrease in fetal weight were observed as compared to control.
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not specified - Reduction in number of live offspring:
- not specified
- Changes in sex ratio:
- not specified
- Changes in litter size and weights:
- not specified
- Changes in postnatal survival:
- not specified
- External malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- When treated wtih 20 and 60 mg/kg/day, reduced ossification of manus and pes were observed in fetus of treated rats.
- Skeletal malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- When treated wtih 20 and 60 mg/kg/day, increased incidences of minor skeletal defects and/or variants were observed in fetus of treated rats.
- Visceral malformations:
- not specified
- Other effects:
- not specified
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 5 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- fetal/pup body weight changes
- external malformations
- skeletal malformations
- Remarks on result:
- other: No effect observed
Fetal abnormalities
- Abnormalities:
- not specified
- Description (incidence and severity):
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
- Treatment related:
- not specified
- Relation to maternal toxicity:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Applicant's summary and conclusion
- Conclusions:
- NOAEL was considered to be 5 mg/kg/day for P and F1 generation when Wistar female rats were treated with Metam-sodium orally by gavage on Days 6-17 of gestation.
- Executive summary:
In a deelopmental toxicity study, Wistar male and female rats were treated with Metam-sodium in the concentration of 0, 5, 20 and 60 mg/kg/day by gavage on Days 6-17 of gestation. Piloerection, salivation, and urinary incontinence were observed in treated rats at 20 and 60 mg/kg/day. No clinical signs were observed in treated rats at 5 mg/kg/day. Decreased in body weight gain and food consumption was observed in treated female rats at 20 and 60 mg/kg/day as compared to control. Similarly, Marginal decreased in body weight gain and food consumption was observed in treated female rats at 5 mg/kg/day as compared to control. In addition, decrease in fetal weight, reduced ossification of manus and pes and increased incidences of minor skeletal defects and/or variants were observed in fetus of treated rats was observed at 20 and 60 mg/kg/day as compared to control. Therefore, NOAEL was considered to be 5 mg/kg/day for P and F1 generation when Wistar female rats were treated with Metam-sodium orally by gavage on Days 6-17 of gestation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.